#United States #Los Angeles #Antibiotics #Metaba #MAX BioPharma

Breakthrough in Antibiotic Development by Metaba and MAX BioPharma

Metaba, LLC and MAX BioPharma, Inc. have recently made exciting strides in their collaboration to create next-generation antibiotics that utilize oxysterol-based mechanisms. This partnership is especially significant given the escalating global health crisis posed by drug-resistant infections, which include serious conditions such as tuberculosis (TB), urinary tract infections (UTIs), Lyme disease, and methicillin-resistant Staphylococcus aureus (MRSA).

The Urgent Need for New Antibiotics

The global landscape of healthcare is increasingly hampered by the rise of bacteria that resist standard antibiotic treatments. Such infections are not only hard to treat but also lead to longer hospital stays, higher medical costs, and increased mortality rates. This alarming trend has created an urgent demand for innovative therapeutic strategies that can effectively combat these resistant pathogens.

In response, Metaba has turned to MAX BioPharma's proprietary Oxysterol Therapeutics® platform to harness the unique properties of oxysterols for developing novel antibiotics. These compounds stand out for their orally bioavailable features and potent bactericidal activity against dangerous bacteria like Mycobacterium tuberculosis.

Partnership Dynamics

Philip Sell, the CEO of Metaba, expressed the gravity of the situation, stating, "Antibiotic resistance is one of the greatest threats to global health, and new therapeutic strategies are urgently needed. Our partnership with MAX BioPharma is enabling the development of truly novel antibiotics that harness oxysterol biology to combat infections in a fundamentally new way."

On the other hand, Farhad Parhami, the CEO of MAX BioPharma, highlighted the excitement surrounding their collaboration, noting, "We have long recognized the unique therapeutic potential of oxysterols, and this partnership with Metaba is a crucial step in translating our technology into innovative antibiotic solutions. The ongoing global crisis of drug-resistant infections underscores the pressing need for effective treatments, and we are optimistic about the potential impact our work can have on patient care worldwide."

Expert Insights

The scientific community recognizes the importance of this initiative. Dr. Edward Jones-López, an infectious disease specialist at Keck Medical Center of USC, remarked on the critical nature of new antibiotic development in light of rising drug resistance. He stated, "Metaba's work in oxysterol-based antibiotics presents a promising and essential strategy to address antimicrobial resistance." Such endorsements from leading experts further validate the noble aims of Metaba and MAX BioPharma's collaboration.

Future Presentations and Developments

Upcoming events will provide more insights into the progress made by these companies. Mr. Sell is scheduled to present the latest research developments at the 2025 Biocom Global Life Science Partnering Investor Conference, which will take place in La Jolla, California, on February 26, 2025. Attendees will gain exclusive insights into Metaba’s findings and strategies for advancing their oxysterol-based antibiotic solutions through rigorous preclinical and clinical trials.

About Metaba, LLC

Founded and based in Santa Monica, California, Metaba, LLC is a biotechnology company dedicated to developing revolutionary antibiotic solutions to address the urgent challenge of antimicrobial resistance. Initially focused on developing adjunctive therapies for tuberculosis, the company has expanded its research efforts through strategic partnerships and pilot projects with various pharmaceutical companies and research institutions. Metaba's work promises to redefine the treatment landscape for infectious diseases by offering new, safer, and more effective alternatives to outdated antibiotic treatments. For further details, please visit metaba.us.

About MAX BioPharma, Inc.

MAX BioPharma, Inc. is a preclinical-stage biopharmaceutical company committed to the development of groundbreaking lipid-based therapeutics for various disabling human diseases. The company's Oxysterol Therapeutics® platform stands at the forefront of innovation across multiple therapeutic disciplines, supported by an extensive intellectual property portfolio. Their oxysterol-based candidates aim to address not only infectious diseases but also cancer, fibrosis, and bone regeneration, further emphasizing the versatility and potential of insights into oxysterols in modern medicine. For additional information, please visit maxbiopharma.com.